Auto-immune disease: The viral route is confirmed

2012-12-19

(Press-News.org) Why would our immune system turn against our own cells? This is the question that the combined Inserm/CNRS/ Pierre and Marie Curie University/Association Institut de Myologie have strived to answer in their "Therapies for diseases of striated muscle", concentrating in particular on the auto-immune disease known as myasthenia gravis. Through the project known as FIGHT-MG (Fight Myasthenia Gravis), financed by the European Commission and coordinated by Inserm, Sonia Berrih-Aknin and Rozen Le Panse have contributed proof of the concept that a molecule imitating a virus may trigger an inappropriate immune response, causing muscular function to deteriorate. These results have been published in Annals of Neurology, accessible on line. Myasthenia, a rare auto-immune disease Myasthenia gravis is a rare auto-immune disease (5,000 to 6,000 patients in France) that produces muscular weakness and exhaustion. It generally affects the facial muscles first, and may then become generalised through the muscles of the limbs or the respiratory muscles, causing respiratory distress. This is due to the production of circulating auto-antibodies that block the acetylcholine receptors (RACh), these neurotransmitters being necessary for transmitting the motor nerve signal to the neuro-muscular junction.

Could a viral infection be the origin of myasthenia? Myasthenia is a multi-factorial disease in which environmental factors seem to play a key triggering role. Viral infections are suspected but it is hard to prove the role of a virus in triggering the condition. In fact, diagnosis of myasthenia is often made months, or even years, after the actual start of the illness when the virus is no longer detectable, even though the signature left by the virus is visible long after the infection.

Proof of the concept of a viral origin contributed by researchers Under the European FIGHT-MG project, the team of researchers managed to decode the trigger for the illness by using a molecule that mimics the RNA double viral strand (Poly(I:C)). To do this, they concentrated on the organ that plays a central role in the disease – the thymus. It is in this gland located in the thorax that the T-lymphocytes mature, these being the key players in immune response that are normally programmed to avoid the development of any auto-immunity. The researchers were thus able to show in vitro that the Poly(I:C) was capable of specifically inducing an over-expression of RACh through thymal epithelial cells, while activating three proteins (the "toll-like" receptor 3 (TLR3), the protein kinase R (PKR) and interferon-beta (IFN-â)); it is this last that produces inflammation in the thymus. At the same time, they analysed pathological thymus glands of myasthenia sufferers in whom they observed over-expression of these same three proteins in the immune system, characteristic of a viral infection. Finally, the researchers also managed to identify the same molecular changes in the thymus glands of mice, after they had been injected with Poly(I:C). After a prolonged injection period, they also observed a proliferation in the mice of B anti-RACh cells, the presence of auto-antibodies blocking the RACh receptors and clinical signs synonymous with the muscular weakness found in myasthenia. These original results show that molecules that mimic a viral infection are capable of inducing myasthenia in the mouse, something that had never been demonstrated before. This set of papers published in the Annals of Neurology provides proof of the concept that a viral infection can cause inflammation of the thymus and lead to the development of auto-immune myasthenia. The next stages of the research will consist in determining which exogenous virus this may be or whether it is a case of the abnormal activation of an anti-viral response by endogenous molecules.

FIGHT-MG (Fighting Myasthenia Gravis) – a European collaboration making giant leaps forward The FIGHT-MG project seeks to determine the genetic and environmental risk factors associated with the occurrence of the illness and its development. The project aims also to identify the key immunological molecules associated with its appearance, and to study the pathogenic mechanisms at the neuromuscular junction, establish new diagnostic tests, as well as new treatments (cellular treatments, immuno-regulatory treatments, immuno-absorption of pathogenic auto-antibodies and other pharmacological treatments). "When one is working on a rare disease, it is essential to work through networking, so as to be able to share our facilities and resources to promote fundamental and clinical research. It is also crucial to communicate permanently with patient associations. It is this combination that enables us to take giant steps in the treatment of rare conditions," explains Sonia Berrih-Aknin. ### FIGHT-MG : http://www.fight-mg.eu/

FIGHT-MG started in December 2009 and will last for four years, with a total budget of about six million euros funded by the European Union (FP7). The project involves 12 partners based in seven European countries: The 12 partners: Inserm (coordinator), France: http://www.inserm.fr/
Hellenic Pasteur Institute (HPI), Greece: http://www.pasteur.gr/?lang=en
Open University of Israel (OUI), Israel: http://www-e.openu.ac.il/
Fondazione Istituto Neurologico "Carlo Besta" (INNCB), Italy: http://www.istituto-besta.com
Oslo University Hospital (OUS), Norway: http://www.oslo-universitetssykehus.no/omoss/english/Sider/side.aspx
Hadassah Hebrew University Medical Center (HMO), Israel: http://www.hadassah-med.com/
Israel Institute of Technology (TECHNION), Israel: http://www1.technion.ac.il/en
University of Paris 6 Pierre and Marie Curie (UPMC), France: http://www.upmc.fr/
University of Basel (UNIBAS), Switzerland: http://www.unibas.ch/
ProteoSys (PSY), Germany: http://www.proteosys.com/
Genopolis Consortium for Functional Genomics (GENOPOLIS), Italy: http://www.genopolis.it/
INSERM TRANSFERT SA (IT), France: http://www.inserm-transfert.fr/fr/

The "Myasthenia" team The "Myasthenia" team, headed by Sonia Berrih-Aknin joined the Institute of Myology directed by Professor T. Voit, just over a year ago in order to get closer to the reference centre for neuromuscular diseases run by Prof B. Eymard, at the Pitié-Salpêtrière Hospital in Paris. The Institute of Myology is an international center of expertise on the muscle and its diseases, a member of the Institute of Biotherapy of rare diseases created by the AFM-Telethon. The Sonia Berrih-Aknin's team is interested in the etiological and physio-pathological mechanisms of myasthenia and innovative treatments that could improve patients' quality of life. Even though winning a European project is very competitive, this team has exceptionally been granted three other projects since 2001, and was responsible for their coordination. Sonia Berrih-Aknin was the coordinator of the "Mechanisms of Myasthenia" project (2001-2005) under FP5, the MYASTAID (2006-2010) project under le cadre du FP6, as well as the Euromyasthenia Project (2006-2009) through the European Public Health Directorate. These projects brought a total of more than fifty teams of clinicians, researchers and associations of sufferers in Europe.

Inserm www.inserm.fr The "French National Health and Medical Research Institute" (Inserm), created in 1964, is a public body of a scientific and technical nature, under the dual auspices of the Ministry of Higher Education and Research and the Ministry of Health. Its researchers are involved in the study of all types of illness, from the commonest to the rarest, through their biological, medical and health of the population research. With a budget of €905 million euros for 2011, Inserm supports some 300 laboratories installed throughout French territory. The teams contain a total of about 13,000 researchers, engineers, technicians and administrators. Inserm is a member of the "Alliance nationale pour les sciences de la vie et de la santé", founded in April 2009 with the CNRS, the CEA, the Inra, the Inria, the IRD, the Institut Pasteur, the Conférence des Présidents d'Université (CPU) and the Conférence des directeurs-généraux de centres hospitaliers régionaux et universitaires. This alliance is part of the policy of reforming the research system so as to better coordinate the role of the various entities involved and to reinforce the position of French research in this sector through coordinated planning.

Inserm is Europe's leading European project instigator, with 28 projects coordinated by the Institute as part of the FP7 scheme.

Source "Implication of dsRNA signalling in the etiology of autoimmune myasthenia gravis"

Perrine Cufi1, MSc, Nadine Dragin, PhD1*, Julia Miriam Weiss, PhD1*, Pilar Martinez-Martinez, PhD2, Marc H. De Baets, MD, PhD2, Régine Roussin, MD 3, Elie Fadel, MD3, Sonia Berrih-Aknin, PhD1 and Rozen Le Panse, PhD1

1 Combined Research Unit - CNRS UMR7215/INSERM U974/UPMC UM76/AIM - Thérapie des maladies du muscle strié, Groupe hospitalier Pitié-Salpêtrière, 105 Boulevard de l'Hôpital, 75651 PARIS Cedex 13 - France. 2 Department of Neuroscience, School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 50, P.O. Box 616, 6200 MD Maastricht, The Netherlands. 3 Département de Chirurgie cardiaque des cardiopathies, Hôpital Marie Lannelongue, 92350 Le Plessis Robinson, France. * These authors contributed equally to this work.

Annals of Neurology DOI: 10.1002/ana.23791

ELSE PRESS RELEASES FROM THIS DATE:

Toward a pill to enable celiac patients to eat foods containing gluten

2012-12-19

Scientists are reporting an advance toward development of a pill that could become celiac disease's counterpart to the lactase pills that people with lactose intolerance can take to eat dairy products without risking digestive upsets. They describe the approach, which involves an enzyme that breaks down the gluten that causes celiac symptoms, in the Journal of the American Chemical Society. Justin Siegel, Ingrid Swanson Pultz and colleagues explain that celiac disease is an autoimmune disorder in which the gluten in wheat, rye or barley products causes inflammation in ...

A new, super-nutritious puffed rice for breakfast cereals and snacks

2012-12-19

A new process for blowing up grains of rice produces a super-nutritious form of puffed rice, with three times more protein and a rich endowment of other nutrients that make it ideal for breakfast cereals, snack foods and nutrient bars for school lunch programs, scientists are reporting. Their study appears in ACS' Journal of Agricultural and Food Chemistry. Syed S.H. Rizvi and colleagues explain that commercial puffed rice is made by steam extrusion. An extruder squeezes rice flour mixed with water through a narrow opening at high temperature and pressure. On exiting ...

Sustainable way to make a prized fragrance ingredient

2012-12-19

Large amounts of a substitute for one of the world's most treasured fragrance ingredients — a substance that also has potential anti-cancer activity — could be produced with a sustainable new technology, scientists are reporting. Published in the Journal of the American Chemical Society, the advance enables cultures of bacteria to produce a substitute for natural ambergris, which sells for hundreds of dollars an ounce. Laurent Daviet, Michel Schalk and colleagues explain that ambergris, a waxy substance excreted by sperm whales, has been prized as a fragrance ingredient ...

Wine and tea are key ingredients in South African plan to grow domestic research

2012-12-19

The South African government is investing in scientific research to foster production of agricultural products like pinotage (the country's signature red wine) and honeybush (source of a tea so fragrant that a potful can perfume an entire house) to create jobs and boost the economy. That effort and others aimed at developing a globally competitive research enterprise are the topics of cover stories in the current issue of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society. Britt E. Erickson, ...

University of Texas at Austin Team develops a microwave-assisted method for producing thin films

2012-12-19

Growth of new materials is the cornerstone of materials science - a highly inter-disciplinary field of science that touches every aspect of our lives from computers and cell phones to the clothes we wear. At the same time, the energy crisis has brought the spotlight on synthesis and growth of materials for clean energy technologies, such as solar cells and batteries. However, researchers in these areas do not simply grow materials —they assemble the atoms and molecules that form so-called thin films on various substrates. It is a process that is highly complex, time-consuming ...

Described a key mechanism in muscle regeneration

2012-12-19

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have described a new selective target in muscle regeneration. This is the association of alpha-enolase protein and plasmin. The finding could be used to develop new treatments to regenerate muscular injuries or dystrophies. The study has been published in PLOS ONE journal. Skeletal muscle has a great regeneration capacity after injury or genetic diseases such as Duchenne muscular dystrophy, the most common neuromuscular disorder in children. This condition is due to a defect in the gene of dystrophin, ...

Experiencing discrimination increases risk-taking, anger, and vigilance

2012-12-19

Experiencing rejection not only affects how we think and feel — over the long-term it can also influence our physical and mental health. New research suggests that when rejection comes in the form of discrimination, people respond with a pattern of thoughts, behaviors, and physiological responses that may contribute to overall health disparities. "Psychological factors, like discrimination, have been suggested as part of the causal mechanisms that explain how discrimination gets 'under the skin' to affect health," says psychological scientist and senior researcher Wendy ...

UC Irvine study of leaping toads reveals muscle-protecting mechanism

2012-12-19

Irvine, Calif., Dec. 19, 2012 — Most people are impressed by how a toad jumps. UC Irvine biologist Emanuel Azizi is more impressed by how one lands. An assistant professor of ecology & evolutionary biology who specializes in muscle physiology and biomechanics, Azizi found that nature's favorite leapers possess a neuromuscular response that's specific to the intensity of a landing – a mechanism that protects muscles from injury upon impact. The research is helping reveal how the nervous system modulates motor control patterns involved with jumping and landing. Azizi's ...

Healthy lifestyle during menopause may decrease breast cancer risk later on

2012-12-19

Obese, postmenopausal women are at greater risk for developing breast cancer and their cancers tend to be more aggressive than those in lean counterparts. A University of Colorado Cancer Center study published in the December issue of the journal Cancer Research shows how this risk might be prevented. "By using nutrient tracers for fat and sugar, we tracked where the body stored excess calories. In lean models, excess fat and glucose were taken up by the liver, mammary and skeletal tissues. In obese models, excess fat and glucose were taken up by tumors, fueling their ...

Protein creates paths for growing nerve cells

2012-12-19

Working with mice, Johns Hopkins scientists have discovered that a particular protein helps nerve cells extend themselves along the spinal cord during mammalian development. Their results shed light on the subset of muscular dystrophies that result from mutations in the gene that holds the code for the protein, called dystroglycan, and also show how the nerve and muscle failings of the degenerative diseases are related. As mammals like mice and humans develop, nerve cells in the brain and spinal cord must form connections with themselves and with muscles to assure proper ...

Microporous crystals for greater food safety – ERC proof of concept grant for researcher at Graz University of Technology

First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study

Auto-immune disease: The viral route is confirmed

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: